Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease  by Eagan, Tomas ML. et al.
Respiratory Medicine (2010) 104, 283e290ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedSystemic mannose-binding lectin is not associated
with chronic obstructive pulmonary diseaseTomas ML. Eagan a,b,*, Pa˚l Aukrust c,d, Per S. Bakke a,e,
Jan Kristian Dama˚s c,d,f, Trude D. Skorge a, Jon A. Hardie a,
Thor Ueland c,g, Tom Eirik Mollnes ha Department of Thoracic Medicine, Haukeland University Hospital, 5021 Bergen, Norway
b Division of Physiology, University of California San Diego, 9500 Gilman Drive La Jolla, CA 92093, USA
c Research Institute for Internal Medicine, Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway
d Section of Clinical Immunology and Infectious Diseases, Rikshospitalet University Hospital, University of Oslo,
N-0027 Oslo, Norway
e Section of Pulmonary Medicine, Institute of Medicine, University of Bergen, N-5021 Bergen, Norway
f Department of Infectious Diseases, St. Olavs Hospital, Olav Kyrres gt. 17, 7006 Trondheim, Norway
g Section of Endocrinology, Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway
h Institute of Immunology, Rikshospitalet University Hospital, University of Oslo, N-0027 Oslo, Norway
Received 13 May 2009; accepted 7 September 2009KEYWORDS
COPD;
Innate immunity;
Mannose-binding lectin* Corresponding author at: Departm
3245.
E-mail address: tomas.eagan@med
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.09.015Summary
Mannose-binding lectin (MBL) deficiency is associated with increased susceptibility to airways
infections and autoimmunity. We examined whether MBL deficiency was more common in
COPD patients, and whether MBL deficiency was associated with COPD severity.
415 COPD patients and 231 healthy subjects, aged 40e75, were examined in 2006/07.
Plasma MBL levels were determined by ELISA. Low or deficient MBL levels were defined as
plasma levels below 500 ng/mL or 100 ng/mL respectively. Logistic regression models deter-
mined factors associated with MBL deficiency; with explanatory variables study category,
sex, age, smoking, comorbid heart disease, and CRP. For COPD severity, explanatory variables
were FEV1, exacerbation history, hypoxia, respiratory symptoms, inhaled steroids, and CRP.
18.2% of healthy subjects and 22.2% of patients had MBL levels below 100 ng/mL (pZ 0.23);
42.9% of healthy subjects and 49.6% of patients had levels below 500 ng/mL (pZ 0.10). After
adjustment for co-variables, patients had an OR (95% CI) of 1.26 (0.7, 2.2) for having MBL levels
below 100 ng/mL compared with healthy subjects, and an OR (95% CI) of 1.06 (0.7, 1.7) forent of Thoracic Medicine, Haukeland University Hospital, N-5021 Bergen, Norway. Tel.: þ47 55 97
.uib.no (T.ML. Eagan).
9 Elsevier Ltd. All rights reserved.
284 T.ML. Eagan et al.having levels below 500 ng/mL. Among the COPD patients, none of the disease variables were
associated with MBL deficiency.
No association was found between MBL deficiency and COPD or COPD severity.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a disease
characterized by loss of alveolar tissue, inflammation in the
small airways and irreversible airways obstruction.1 Almost
all COPD patients have a history of inhalation of harmful
airborne particles, with tobacco being the most common.
Patients with COPD frequently experience exacerbations,
with worsening of their symptoms and most often signs of
co-existing viral or bacterial infection.2 The tendency to
exacerbate differ considerably between patients, although
being more common in patients with more severe disease.3
The inflammation seen in COPD patients is predomi-
nantly innate, with a large influx of neutrophils and
macrophages, but also CD8þ T cells.4,5 COPD patients are
frequently colonized by potentially pathogenic bacteria,6e8
and possibly by viruses.9 Whether colonization plays a role
in the pathogenesis of COPD or the tendency to exacerbate
is not yet resolved. However, a plausible hypothesis is that
colonization and/or repeated infections in the lower
airways contribute to sustained airways inflammation. If so,
increased susceptibility to airways infections could poten-
tially play a part in the progression of COPD.
Mannose-binding lectin (MBL) is a circulatory protein
that binds to carbohydrates on the surface of many
different pathogens. MBL-pathogen binding leads to acti-
vation of the lectin complement pathway by serine prote-
ases, in particular MBL-associated serine protease 2 (MASP-
2), and cleaving of complement factor 4 (C4) and C2. This
leads to conversion of C3 into C3a and C3b and ultimately of
C5 into C5a and C5b-9. The activation products lead to
recruitment of inflammatory cells, opsonization, and the
removal of the pathogen.
MBL is coded for by the gene MBL2, of which several
polymorphisms exist that can lead to varying degrees of
functional MBL deficiency. MBL deficiency has been asso-
ciated with an increased risk of severe respiratory infec-
tions,10,11 but also autoimmune diseases like systemic lupus
and rheumatoid arthritis.12,13
The aim of the current study was to examine whether
having low levels of MBL or MBL deficiency was more
frequently present in a group of COPD patients than in
subjects without COPD, and whether specific COPD char-
acteristics like severity, exacerbation frequency, including
those that are induced by recurrent bacterial infections,
and symptoms were associated with MBL deficiency.
Methods
Study population
Patients with COPD and subjects without COPD were exam-
ined in 2006 and 2007, in the baseline survey of the Bergen
COPD Cohort Study, conducted at Haukeland UniversityHospital inWestern Norway. Patients were recruited from the
outpatient clinic, previous COPD studies, or referred from
privatepractitioners outside the hospital, or other hospitals in
Western Norway. Subjects without COPDwere recruited from
a previous general population survey from the same
geographical area in Western Norway.14 All COPD patients
were required to have a smoking history of at least 10 pack
years, a FEV1/FVC ratio of less than 0.7, and an FEV1 of less
than 80% predicted. All subjects without COPD had an FEV1/
FVC ratio above 0.7, and an FEV1 ofmore than 90% predicted.
All participants were at least 40 years of age at inclusion, and
known inflammatory disorders like rheumatoid arthritis, or
any active cancer, were considered a cause for exclusion. The
selection of the study population has recently been published
in greater detail.15 In the current study, only subjects from
whomwe had adequate plasma samples and who did not take
oral steroids were inlcuded; 646 out of 666 potential subjects.
Written information was provided and written consent
was obtained prior to inclusion. There was no financial
reimbursement for participation. However, an attempt was
made to assist participants with health issues uncovered
during the examination. The regional ethical committee
approved the study.
Data collection
A physician examined all participants, took a detailed
medical history including smoking history and comorbid-
ities, and performed arterial blood gas sampling. Blood
gases were measured within 5 min on a Radiometer ABL 520
blood gas analyzer, lung function measurements were
conducted on a Viasys Masterscope, and bioelectrical
impedance measured with a Bodystat 1500. Hypoxemia was
defined as an arterial partial oxygen pressure (PaO2) of less
than 8.0 kPa at rest.
FEV1 in percent predicted was calculated based on
Norwegian pre-bronchodilatation reference values.16 When
categorizing patients into severity by Global initiative of
Obstructive Lung Disease (GOLD) categories, only FEV1 in
percent predicted were taken into account, and PaO2 was
treated as an independent variable.
The bioelectrical impedance measurements were used
to estimate fat free mass. The fat free mass index (FFMI) is
defined as the fat free mass (kg) divided by square height
(m2). An FFMI value below 90% of predicted was considered
a marker of serious loss of lean body mass.17
The presence of respiratory symptoms was assessed with
a Norwegian questionnaire previously used in several
general population studies.18,19
Laboratory measurements
Peripheral venous blood was drawn into pyrogen-free blood
collection tubes with EDTA as anticoagulant and centri-
fuged within 30 min at 2150 g (15 min at 4 C). All samples
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linked immunosorbent assay (Hycult biotechnology, Uden,
The Netherlands). The samples were analysed in one batch
and the assay was performed according the instructions of
the manufacturer. The assay is based on the following
principle: plasma is incubated in mannan-coated microtiter
wells and MBL bound to the mannan coat is detected by an
anti-MBL antibody. The optical density is related to a stan-
dard cure with known concentration of MBL. Thus, this
assay is a quantitative MBL assay based on a combination of
the functional property of MBL to bind to mannan and
thereafter immunochemical detection of the amount of
MBL bound. MBL deficiency was defined as a measured level
in plasma of less than 100 ng/mL,20 whereas levels below
500 ng/mL arbitrarily were defined as low.
Plasma levels of C-reactive protein (CRP) were measured
using enzyme immunoassays, previously described.15
Statistical analyses
Differences in prevalence of deficient or low MBL among
study categories were examined by chi-square tests. Both
unconditional and conditional logistic regression analyses
were used to evaluate the association between study
category and MBL levels, adjusted for sex, age, smoking,
comorbid heart disease and CRP. Similarly, two uncondi-
tional logistic regression models were fitted to examine
the association between COPD disease characteristics and
MBL levels, adjusted for sex, age, smoking habits, CRP,
and all other COPD characteristics examined. Power
calculations and statistical analyses were all performed
with Stata 10.1.Table 1 Baseline characteristics of the study population.
COPD patients (nZ 415
Sex
Women 39.5
Men 60.5
Age
Mean (SD) 63.5
(62.8e64.2)
Smoking habits
Never 0.0
Ex 55.7
Current 44.3
Pack years smoked
0 0.0
1e19 14.5
20e39 41.9
40þ 43.6
Known coronary heart disease
No 82.3
Yes 17.7
plasmaCRP (ug/mL)
Median (IQ range) 2.2
(0.7e4.6)
a Chi-square for categorical variables, t-test for age, Wilcoxon for C
b Chi-square is not including the category with no smoking.Results
The characteristics of the study population are presented in
Table 1. Patients were significantly different from subjects
without COPDby sex, age, andknowncomorbidheart disease.
Subjects without COPD who were current- or ex-smokers had
a lower average smoking history in terms of pack years.
Twenty-two percent of COPD patients had measured MBL
levels below 100 ng/mL and 50% of the COPD patients had
measured MBL levels below 500 ng/mL. This was not
significantly different from the control group where 18%
and 43% of the individuals showed MBL levels below 100 ng/
ml and 500 ng/ml, respectively (Table 2).
The lack of association between study category and MBL
levels held true after adjustment for the co-variables
(Table 3). Thus, although the adjusted odds ratios for
having low MBL levels were slightly higher among COPD
patients than subjects without COPD after adjustment for
co-variables, this failed to reach statistical significance.
Among the co-variables, the only significant associations
were a greater chance of having MBL levels below 500 ng/
mL among women and participants with known coronary
heart disease (Table 3). To ensure that the age difference
between the patients and subjects without COPD did not
affect the results, a subset of 80 subjects without COPD
were age-matched with 400 patients, and examined with
conditional logistic regression. With this approach, the OR
(95% CI) for having MBL levels below 100 ng/mL was 1.19
(0.6e2.2), and 1.12 (0.7e1.8) for having MBL levels below
500 ng/mL. Thus, the conditional regression yielded the
same results; no significant difference between COPD
patients and subjects without COPD.) Non-COPD subjects (nZ 231) pa
0.03
48.5
51.5
<0.01
54.7
(53.7e55.8)
<0.01b
19.5
10.4
70.1
<0.01b
19.5
25.5
36.8
18.2
<0.01
96.1
3.9
<0.01
4.0
(1.8e10.0)
RP.
Table 2 Percentage of subjects having low or deficient MBL levels in plasma.
Levels below 100 ng/mL Levels below 500 ng/mL
n pa pa
Study category 0.23 0.10
Healthy subjects 231 18.2 42.9
COPD patients 415 22.2 49.6
Sex 0.35 0.06
Women 276 22.5 51.5
Men 370 19.5 44.1
Age 0.65 0.23
40e54 173 19.7 41.6
55e64 257 22.6 49.0
65e75 216 19.4 49.5
Smoking habits 0.13 0.01
Never 45 17.8 44.4
Ex 255 24.7 54.5
Current 346 18.2 42.2
Pack years smoked 0.23 0.59
0 45 17.8 44.4
1e19 119 14.3 42.0
20e39 259 22.4 49.0
40þ 223 22.9 48.4
Coronary heart disease 0.25 0.02
No 559 20.0 45.4
Yes 82 25.6 59.8
plasmaCRP (ug/mL) 0.90 0.95
0e6 444 20.5 47.5
6e12 107 22.4 46.7
12þ 94 20.2 45.7
a Chi-square test.
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in COPD patients by disease severity, respiratory symp-
toms, known coronary heart disease, use of inhaled
steroids, and CRP is presented in Table 4. Of all categoriesTable 3 The adjusted Odds Ratio (95% CI) for having low or de
MBL levels below 100 ng/
OR (95%
Study category
Healthy subjects 1
COPD patients 1.26 (0.7e
Sex
Women 1
Men 0.79 (0.5e
Age
40e54 1
55e64 0.98 (0.6e
65e75 0.71 (0.4e
Smoking habits
Never 1
Ex 1.25 (0.5e
Current 0.86 (0.4e
Known coronary heart disease
No 1
Yes 1.51 (0.8e
plasmaCRP (ug/mL)
per unit increase 0.99 (0.97examined, the only statistically significant difference in
prevalence of MBL levels above and below 100 ng/mL was
seen for GOLD category with a lower percentage of MBL
deficiency in the GOLD stage III group. No statisticallyficient MBL levels in plasma.
mL MBL levels below 500 ng/mL
CI) OR (95%CI)
1
2.2) 1.06 (0.7e1.7)
1
1.2) 0.67 (0.5e0.9)
1
1.7) 1.17 (0.8e1.8)
1.3) 1.04 (0.6e1.7)
1
3.3) 1.38 (0.7e2.9)
2.1) 0.87 (0.4e1.8)
1
2.7) 1.82 (1.1e3.0)
e1.01) 1.00 (0.98e1.02)
Table 4 Percentage of COPD patient having low or deficient MBL levels in plasma.
Levels below 100 ng/mL Levels below 500 ng/mL
n pa pa
Disease severity
GOLD categoryb 0.04 0.38
II (FEV1 50e80) 194 25.8 53.1
III (FEV1 30e50) 173 16.2 47.4
IV (FEV1 0e30) 48 29.2 43.8
Free Fat Mass
Index < 90% of predicted
0.10 0.47
No 329 23.1 50.2
Yes 81 14.8 45.7
Experienced 2 or more
exacerbations last
yearc
0.32 0.40
No 342 23.1 50.6
Yes 73 17.8 45.2
Hypoxemia (PaO2<8.0kPa) 0.48 0.63
No 328 23.8 49.4
Yes 47 19.2 53.2
Respiratory symptoms
Chronic cough 0.12 0.89
No 214 25.2 49.1
Yes 191 18.9 49.7
Phlegm 0.55 0.38
No 170 23.5 52.4
Yes 242 21.1 47.9
Dyspnea (grade III) 0.46 0.54
No 222 21.2 47.8
Yes 173 24.3 50.9
Comorbidities
Known coronary heart disease 0.44 0.06
No 332 21.4 47.3
Yes 83 25.3 59.0
Medications 22.6 47.2
Inhaled steroids 0.34 0.28
No 125 19.2 45.6
Yes 290 23.5 51.4
Inflammation
plasmaCRP (ug/mL) 0.32 0.97
0e6 258 20.5 49.6
6e12 73 28.8 50.7
12þ 84 21.4 48.8
a chi-square test.
b based on pre BD ref values.
c requiring treatment with either antibiotics or oral steroids.
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below 500 ng/mL.
After adjustment for all co-variables, the association
between GOLD category and MBL levels below 100 ng/mL
was no longer evident (Table 5). Indeed, there was no
characteristic of COPD that proved significantly associated
with having MBL levels below 100 ng/mL. Similarly, having
comorbid coronary heart disease was the only factor asso-
ciated with having a level of MBL below 500 ng/mL among
COPD patients, after full adjustment (Table 5).Discussion
In this cross-sectional study of 415 COPD patients and 231
subjects without COPD, no evidence was found to support
that low MBL levels or MBL deficiency should be more
common among patients with COPD. Further, no evidence
was found to support that low MBL levels or MBL deficiency
was more common in patients with more severe disease, or
more frequent exacerbations including recurrence of lower
respiratory tract infections.
Table 5 The adjusted OR (95% CI) for having low or deficient MBL levels in plasma by patient characteristics.a
MBL levels below 100 ng/mL MBL levels below 500 ng/mL
OR (95%CI) OR (95%CI)
GOLD category
II (FEV1 50e80) 1 1
III (FEV1 30e50) 0.74 (0.4e1.3) 0.96 (0.6e1.6)
IV (FEV1 0e30) 1.71 (0.7e4.3) 1.07 (0.5e2.5)
Free Fat Mass Index < 90% of
predicted
No 1 1
Yes 0.71 (0.3e1.5) 0.91 (0.5e1.6)
Experienced 2 or more
exacerbations last year
No 1 1
Yes 0.79 (0.3e1.8) 0.81 (0.4e1.6)
Hypoxemia (PaO2<8.0kPa)
No 1 1
Yes 0.56 (0.2e1.4) 1.10 (0.6e2.2)
Chronic coughb
No 1 1
Yes 0.76 (0.4e1.4) 1.19 (0.7e2.0)
Phlegmb
No 1 1
Yes 0.93 (0.5e1.6) 0.84 (0.5e1.6)
Dyspnea (grade III)
No 1 1
Yes 1.12 (0.6e2.0) 1.11 (0.7e1.8)
Known coronary heart disease
No 1 1
Yes 1.48 (0.8e2.9) 2.10 (1.1e3.8)
Inhaled steroids
No 1 1
Yes 1.31 (0.7e2.5) 0.94 (0.6e1.6)
plasmaCRP (ug/mL)
per unit increase 1.00 (0.98e1.03) 1.00 (0.98e1.02)
a all factors are also adjusted for sex, age, and smoking habits in addition to all listed variables.
b due to colinearity between phlegm and chronic cough, only one of these two variables could be added to the model at a time.
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Firstly, there were significant differences between the
COPD patients and subjects without COPD, in terms of age
and smoking load. This reflected a lack of strict matching
on any one variable. However, neither sex nor age in either
COPD patients or subjects without COPD was associated
with differences in measured MBL levels. With the large
number of participants, this study had enough power to
enable multivariate analyses, adjusting for differences in
sex, age and smoking. And finally, the results from
a conditional logistic regression analyses confirmed the
findings. Thus, there is no reason the differences between
the demographics of COPD patients and subjects without
COPD should have impacted the final results.
Secondly, with the current sample size and an alpha
level of 0.05, the current study has the power (bZ 0.91)
to detect a difference in prevalence of MBL deficiency of
10%. Thus, if the prevalence of MBL deficiency in the
general population were 10%, it would have to be 20%
among the COPD patients. Exacerbation frequency wouldperhaps be the most sensitive variable to an effect of MBL
deficiency if such exists. A recent previous study on MBL
deficiency and COPD examined the chance of hospital
admittance for infective exacerbations among 82 COPD
patients over a two-year period.21 In that study, 45% of
the patients with more than one hospital admissions had
a MBL deficient genotype, compared with 15% among
patients with no hospital admissions. With the current
sample size, this study had the power (bZ 0.92) to detect
a difference in prevalence of low MBL levels from 40%
among subjects with frequent exacerbations to 20% in
patients without frequent exacerbations. It is worth
noting that the trend in the current study was actually
opposite. COPD patients with frequent exacerbations had
a lower prevalence of MBL deficiency, and lower odds for
having MBL deficiency after adjustment for co-variables,
supporting the validity of the lack of difference in MBL
levels in the two groups.
Thirdly, the information on exacerbations the last 12
months requiring treatment was obtained by interview by
MBL and COPD 289a physician. We thus lack specific information on type of
pathogen responsible for the exacerbations. We must
caution that MBL deficiency could be an important risk
factor for infections with some pathogens and not others.
Thus, future studies should include information on specific
pathogens if possible.
Finally, different methods are used for quantification of
MBL. Since MBL in plasma is present in different oligomeric
forms, the results will be influenced by the method used.
Assays based on double antibody sandwich techniques will
rely on the actual antibodies used and the concentration
will vary depending on the antigenic properties of MBL
molecules not necessarily related to the function.22 In the
present study we have used an assay based on the combi-
nation of the functional ability of MBL to bind to mannan
and the antigenic presentation of an epitope used for
detection. This method has the advantage over standard
double-antibody assays and traditional functional C4
binding assays, namely that it quantifies MBL on the basis on
its interaction with the ligand, independent of the
secondary functional activity including activation of
complement as well as binding to putative receptors, which
cannot be discriminated in a single assay. It should be noted
that the current assay is limited to detection of MBL and
that other proteins participating in the complement lectin
pathway, like the Mannose-binding lectine associates serine
proteases (MASPs) and ficolins, are not included.
Worldwide, the prevalence of MBL deficiency haplotypes
has recently been estimated to be 22% for the deficiency
haplotypes, and 13 and 15% for the low and intermediate-
producing haplotypes respectively.23 This is in reasonable
accordance with the plasma levels measured in the current
study. However, a direct comparison between MBL plasma
levels and genotypes should be made with caution. Plasma
level of MBL is largely explained by which haplotype one
carries, where some haplotypes lead to intermediate to low
levels, other to deficiency.24 For the whole population there
is a reasonably good correlation between genotypes and
concentration, but for each individual the genotype cannot
predict the MBL level.20 Thus, the MBL levels can vary
tenfold between individuals with the same haplotype 25 and
genotyping alone is not a complete substitution for
measuring MBL levels in clinical studies.
MBL deficiency has been shown to be a diseasemodifier in
a number of clinical conditions, including inflammatory and
infectious diseases.12,13,26e30 COPD could be seen as a likely
candidate for a disease where MBL deficiency was a modi-
fying factor. COPD has a strong inflammatory component,
dominated by factors from the innate immune system. The
airways of COPD patients are frequently colonized by various
microorganisms, the significance ofwhich is uncertain. COPD
exacerbations are mostly infectious in origin, and likely to
negatively affect the progression of the disease.31,32
However, although there are some previous studies on the
risk for pulmonary infections in relation to low MBL levels in
other diseases, very little evidence is available for COPD. In
an interventional study with 11 COPD patients undergoing
treatment with azithromycin and 10 controls, it was found
that MBL in bronchial alveolar lavage fluid was lower in COPD
patients than in the controls.33 Plasma MBL was not
measured, and given the methodological concerns in
measuring local MBL and the possible differences in local andsystemic levels, these data cannot be compared with the
current study. However, we cannot rule out that low MBL
levelswithin thepulmonarymicroenvironmentmaybe linked
to COPD severity and this will have to be further examined in
forthcoming studies.
Despite reports indicating that MBL participate in
multiple disease processes, substantial controversy remains
over how large a role MBL deficiency may play as a risk
factor for disease. There are several studies showing little
negative effect of having low or deficient MBL levels,34e38
and even beneficial effects of MBL deficiency have under-
scored a possible role for MBL as a double-edged sword.39
From an evolutionary standpoint, the high population
prevalence of haplotypes responsible for lower levels of
MBL could be explained either by the polymorphisms not
affecting survival, or that low or intermediate levels were
beneficial in some situations, as has been suggested for
mycobacterial disease.40,41 However, a reasonably strong
argument for evolutionary neutrality was recently made by
Verdu et al.23 Thus, the emerging consensus is that immu-
nological redundancy prevents MBL deficiency to be a major
risk factor for disease in the general population. However,
for certain diseases MBL deficiency acts as a disease
modifier, in particular when combined with other immu-
nological abnormalities or immunodeficiencies.26
To our knowledge, this is the first study to specifically
examine plasma levels of MBL in COPD patients compared
with subjects without COPD. Further, the size of the study
allows for examination of different factors related to the
severity of COPD, with adjustments for many co-variables.
Thefindings of the current study indicate that having lowMBL
levels or MBL deficiency is not a major factor in the patho-
genesis of COPD, or in the rateof progression of thedisease.A
final analysis of whether MBL deficiency is a risk factor for
COPD exacerbations will require a longitudinal follow-up.
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